联系我们
联系人：陈先生
产品展示
VEGFR2 Human/重组人血管内皮生长因子受体2
点击次数：968
价格：￥电议
更新日期：2026/8/24 23:18:11
生 产 地：欧洲
产品型号：
商家名片
陈**
联系我时，请说明是阿仪网看到的，谢谢!
- 电话: 05*******891
- 手机: 18******628
- 微信:
- 交换名片后展示联系方式 → →
相关标签：VEGFR2,Human,重组人血管内皮生长因子受体2
详细内容
慧嘉生物您实验身边的好伙伴
为客户提供“最高品质的产品”和“最优质的服务”
AssayBiotech CUSABIO Immunoway Santa Abcam Cst jackson Pierce Sigma Amresco Qiagen Cayman abnova millipore invitrogen merk ebioscience prospec lifespan BD
欢迎广大客户咨询，另有大量宣传海报和小礼品赠送。
网站：www..com
Q Q：
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
Synonyms KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. Introduction Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation.
Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. Description Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding.
The sKDR is purified by proprietary chromatographic techniques. Source Insect Cells. Physical Appearance Sterile Filtered White lyophilized （freeze-dried） powder. Formulation KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. Solubility It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. Stability Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C.
For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）.
Please prevent freeze-thaw cycles. Purity Greater than 95.0% as determined by（a） Analysis by RP-HPLC.
（b） Analysis by SDS-PAGE. Biological Activity The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. Amino Acid Sequence A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. Usage ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
VEGFR2 Human/重组人血管内皮生长因子受体2
产品编号：PKA-242
产品规格：2μg/10μg/1mg
产品规格：2μg/10μg/1mg
| Synonyms | KDR D1⁻⁷, sKDR D1⁻⁷, Kinase ｉnsert domain receptor, Protein-tyrosine kinase receptor Flk-1, CD309, type III receptor tyrosine kinase, FLK1, VEGFR-2. |
| Introduction | Endothelial cells express three different vascular endothelial growth factor （VEGF） receptors, belonging to the family of receptor tyrosine kinases （RTKs）. They are named VEGFR-1 （Flt-1）, VEGFR-2 （KDR/Flk-1）, VEGFR-3 （Flt-4）. Their expression is almost exclusively restricted to endothelial cells, but VEGFR-1 can also be found on monocytes. All VEGF-receptors have seven immunoglobulin-like extracellular domains, a single transmembrane region ａnd an intracellular split tyrosine kinase domain. VEGFR-2 has a lower affinity for VEGF than the Flt-1 receptor, but a higher signaling activity. Mitogenic activity in endothelial cells is mainly mediated by VEGFR-2 leading to their proliferation. Differential splicing of the flt-1 gene leads to the formation of a secreted, soluble variant of VEGFR-1 （sVEGFR-1）. No naturally occuring, secreted forms of VEGFR-2 have so far been reported. The binding of VEGF165 to VEGFR-2 is dependent on heparin. |
| Description | Soluble VEGFR-2 Human Recombinant produced in baculovirus is monomeric, glycosylated, polypeptide having a molecular mass of 116 kDa. The soluble receptor protein contains only the first 7 extracellular domains, which contain all the information necessary for ligand binding. The sKDR is purified by proprietary chromatographic techniques. |
| Source | Insect Cells. |
| Physical Appearance | Sterile Filtered White lyophilized （freeze-dried） powder. |
| Formulation | KDR was lyophilized from a concentrated （1 mg/ml） sterile solution containing 25mM MES pH-5.5 ａnd 100mM NaCl. |
| Solubility | It is recommended to reconstitute the lyophilized VEGFR2 in sterile water not less than 100 μg/ml, which can then be further diluted to other aqueous solutions. |
| Stability | Lyophilized VEGFR-2 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution FLK1 should be stored at 4°C between 2⁻⁷ days ａnd for future use below -18°C. For long term storage it is recommended to add a carrier protein （0.1% HSA or BSA）. Please prevent freeze-thaw cycles. |
| Purity | Greater than 95.0% as determined by（a） Analysis by RP-HPLC. （b） Analysis by SDS-PAGE. |
| Biological Activity | The activity of VEGFR-2 D1⁻⁷ was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors. The ED50 for this effect is typically 10.0 ng/ml. |
| Amino Acid Sequence | A SVGLPSVSLD LPRLSIQKDI LTIKANTTLQ ITCRGQRDLD WLWPNNQSGS EQRVEVTECS DGLFCKTLTI PKVIGNDTGA YKCFYRETDL ASVIYVYVQD YRSPFIASVS DQHGVVYITE NKNKTVVIPC LGSISNLNVS LCARYPEKRF VPDGNRISWD SKKGFTIPSY MISYAGMVFC EAKINDESYQ SIMYIVVVVG YRIYDVVLSP SHGIELSVGE KLVLNCTART ELNVGIDFNW EYPSSKHQHK KLVNRDLKTQ SGSEMKKFLS TLTIDGVTRS DQGLYTCAAS SGLMTKKNST FVRVHEKPFV AFGSGMESLV EATVGERVRI PAKYLGYPPP EIKWYKNGIP LESNHTIKAG HVLTIMEVSE RDTGNYTVIL TNPISKEKQS HVVSLVVYVP PQIGEKSLIS PVDSYQYGTT QTLTCTVYAI PPPHHIHWYW QLEEECANEP SQAVSVTNPY PCEEWRSVED FQGGNKIEVN KNQFALIEGK NKTVSTLVIQ AANVSALYKC EAVNKVGRGE RVISFHVTRG PEITLQPDMQ PTEQESVSLW CTADRSTFEN LTWYKLGPQP LPIHVGELPT PVCKNLDTLW KLNATMFSNS TNDILIMELK NASLQDQGDY VCLAQDRKTK KRHCVVRQLT VLERVAPTIT GNLENQTTSI GESIEVSCTA SGNPPPQIMW FKDNETLVED SGIVLKDGNR NLTIRRVRKE DEGLYTCQAC SVLGCAKVEA FFIIEGA. |
| Usage | ProSpec＇s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals. |
VEGFR2,Human,重组人血管内皮生长因子受体2
